Delivery Order SPE2DB20D1100-SPE2DB25FD9K4
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $1,023.62 firm fixed-price delivery order for Dexcom G7 sensors, with an ultimate completion date of September 5, 2025. This competitively awarded contract, issued on September 4, 2025, represents a child order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,007.81 to AmerisourceBergen Drug Corp for Dexcom G7 sensors on June 25, 2025, with completion scheduled for June 26, 2025. This firm fixed price, non-set-aside delivery order represents a continuation of federal medical supply procurement through the company's existing contract vehicle with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical and medical device distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,071.44 to AmerisourceBergen Drug Corp for Dexcom G7 sensors, with an ultimate completion date of September 18, 2025. This non-competitive, firm fixed-price delivery order was issued under a larger indefinite delivery contract (IDC) vehicle, representing a routine procurement of continuous glucose monitoring devices for military healthcare support. The contract was awarded to AmerisourceBergen's corporate office in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,031.20 to AmerisourceBergen Drug Corp for Dexcom G7 sensors. This firm fixed-price contract, awarded on August 20, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The award carries no set-aside designation and will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,287.63 to AmerisourceBergen Drug Corp for Dexcom G7 sensors on September 15, 2025, with completion expected by September 16, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order will be fulfilled from the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $1,546.80 to AmerisourceBergen Drug Corp for the supply of Dexcom G7 sensors. This contract was competitively awarded with no set-aside designation and carries a firm fixed price structure with an ultimate completion date of August 12, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $1,031.20 to AmerisourceBergen Drug Corp for Dexcom G7 sensors on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a firm fixed price, non-set-aside contract with performance at the contractor's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which...
- The Defense Logistics Agency awarded a delivery order valued at $1,493.49 to AmerisourceBergen Drug Corp for Dexcom G7 sensors, with a completion date of July 21, 2025. This firm fixed-price delivery order, issued on July 18, 2025, represents a competitively awarded transaction with no set-aside designation. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,498.10 to AmerisourceBergen Drug Corp for Dexcom G7 continuous glucose monitoring sensors. This competitively awarded, firm fixed-price contract has an ultimate completion date of August 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under AmerisourceBergen's broader federal medical supply portfolio and reflects...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,474.88 to AmerisourceBergen Drug Corp for the supply of Dexcom G7 sensors. This firm fixed price, non-competitive delivery order was issued on August 8, 2025, with an ultimate completion date of August 11, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's substantial role as a federal medical supply provider,...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD9K4Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,031.20 to AmerisourceBergen Drug Corp for Dexcom G7 sensors. The contract, which was competitively awarded with no set-aside designation, is effective through August 11, 2025, and utilizes firm fixed pricing. AmerisourceBergen will perform fulfillment from its Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen's IDC serves as a global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical devices to support military healthcare programs worldwide. The Dexcom G7 sensors ordered through this delivery order are continuous glucose monitoring devices used in diabetes management, reflecting the company's established portfolio of specialty medical supplies and equipment. The underlying IDC represents DLA's strategic approach to pharmaceutical procurement, with plans underway to establish Pharmaceutical Prime Vendor Global Program Generation V contracts across multiple regions with potentially multiple contractors, leveraging flexible contract vehicles to serve the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 8/8/25 |